AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NEW DELHI, May 1 Asia Pulse - Norwegian government has intervened in a high-profile case filed by Novartis against Indian patent laws by asking the drug company to withdraw the litigation.
"India contributes in very significant ways to the overall production capacity for life saving generic drugs, with major exports to developing countries. It is important for global health that this contribution can continue... I will encourage you to consider to withdraw your case against India," Norwegian Minister of International Development Erik Solheim said in a letter to Novartis International Managing Director, Chairman and CEO Daniel Vasella.
Novartis, which is headquartered in Switzerland, had filed a case in Chennai High Court challenging Indian Patent (Amendment) Act's clause that does not grant patents to medicines, which are new forms of an existing drug or "ever-greened" rather than innovations.
The case was filed after Patent Office in Chennai refused to give patent to the Novartis leukaemia drug Gleevec on the grounds that it was "ever-greened".
Source: HighBeam Research, NORWAY ASKS NOVARTIS TO WITHDRAW PATENT CASE AGAINST INDIA.